Teladoc stock holds steady as Stifel maintains $8 price target

Published 30/07/2025, 16:20
Teladoc stock holds steady as Stifel maintains $8 price target

Investing.com - Teladoc Health Inc (NYSE:TDOC) received a reiterated Hold rating from Stifel on Wednesday, with the firm maintaining its $8.00 price target for the telehealth provider. According to InvestingPro data, the stock is currently trading below its Fair Value, with shares down over 12% in the past week alone.

Teladoc reported second-quarter results with a modest revenue beat, though organic revenue declined 3-4% on a constant currency basis. The company delivered approximately $70 million in EBITDA, exceeding the consensus estimate of $63 million. InvestingPro data shows the company maintains a healthy gross profit margin of 70.5%, though it faces profitability challenges with negative earnings expected this year.

International operations emerged as Teladoc’s primary growth driver, expanding 10-11%, while U.S. business continued to contract by 4%. The company’s BetterHelp segment, representing 38% of revenue, faces competitive pressures, while its Integrated Care unit (62% of revenue) confronts broader secular challenges. Despite these headwinds, the company maintains a solid current ratio of 1.68, indicating adequate liquidity to manage near-term obligations.

Teladoc’s 2025 guidance projects organic revenue to decline 4-5% on a constant currency basis, with EBITDA of approximately $280 million, largely in line with expectations but slightly improved from previous forecasts.

Stifel highlighted two potential growth initiatives: integrating insurance payments for BetterHelp members to increase penetration and reduce churn, and using technology to transform the Integrated Care segment from a transactional urgent care model to a longitudinal relationship model covering a broader spectrum of care.

In other recent news, Teladoc reported its second-quarter 2025 earnings, surpassing expectations with an earnings per share of -$0.19, compared to the forecast of -$0.26. The company’s revenue also exceeded projections, reaching $631.9 million against the anticipated $622.54 million. Despite these positive results, Teladoc chose not to raise its full-year 2025 guidance. Needham reiterated its Hold rating on Teladoc following the earnings report. Meanwhile, Cantor Fitzgerald lowered its price target for Teladoc from $12 to $10, citing challenges in the company’s BetterHelp mental health service. Cantor Fitzgerald also adjusted its EBITDA estimates for Teladoc, reducing them to $266 million for 2025 and $290 million for 2026. These developments reflect ongoing evaluations by analysts regarding Teladoc’s financial outlook and strategic positioning.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.